On Friday, Shares of Office Depot, Inc. (NASDAQ:ODP), lost -1.46% to $7.45.
Office Depot declared results for the second quarter ended June 27, 2015.
Divisional Results
North American Retail Division
Retail Division sales were $1.3 billion in the second quarter of 2015, a decline of 8% contrast to the preceding year period, primarily due to planned store closures in the fiscal twelve months through June 27, 2015. Same-store sales raised 1%, driven largely by transferred sales from closed stores and raised operational effectiveness.
Retail Division operating income was $42 million, or 3.1% of sales, in the second quarter of 2015 contrast to an operating loss of $6 million, or 0.4% of sales, in the second quarter of 2014. The improvement from the preceding year quarter resulted largely from a decrease in occupancy costs driven by store closures, a decrease in selling, general and administrative expenses counting advertising and payroll, in addition to favorable legal settlements and an improvement in the gross margin rate; all of which were partially offset by the negative flow-through impact of lower sales.
Office Depot ended the second quarter of 2015 with a total of 1,626 retail stores in the North American Retail Division. During the quarter, the company closed 99 stores.
Office Depot, Inc., together with its auxiliaries, supplies office products and services. The company’s North American Retail division sells an assortment of merchandise, counting office supplies, technology products and solutions, business machines and related supplies, facilities products, and office furniture under various brands through its chain of office supply stores.
Shares of Novavax, Inc. (NASDAQ:NVAX), declined -5.17% to $10.83, during its last trading session.
Novavax declared that Stanley C. Erck, President and CEO, will present at the Wedbush PacGrow Healthcare Conference.
Conference details are as follows:
Date: Wednesday, August 12, 2015, at 12:45 p.m. US Eastern Time.
Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology.
Finally, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), ended its last trade with -23.62% loss, and closed at $10.90.
BioCryst Pharmaceuticals declared financial results for the second quarter ended June 30, 2015.
Second Quarter Financial Results
For the three months ended June 30, 2015, revenues raised to $25.8 million from $1.5 million in the second quarter of 2014. Revenue in the quarter was primarily due to the partial recognition of the upfront payment to BioCryst resulting from the licensing of RAPIVAB(R) (peramivir injection), in addition to a noteworthy enhance in partnership revenue associated with BCX4430 development as a medical countermeasure for Ebola virus and other filovirus diseases.
Research and development expenses for the quarter raised to $16.5 million from $11.1 million in the second quarter of 2014. The enhance in 2015 R&D expenses, as contrast to 2014, was the result of raised R&D expenses associated with the Company’s HAE and BCX4430 development programs. The more substantial enhance was related to development expenses associated with the HAE portfolio and resulted from higher spending for continued development of avoralstat, formerly known as BCX4161, and expenses for second generation compound development, counting BCX7353.
General and administrative expenses for the second quarter 2015 raised to $3.5 million contrast to $2.0 million in 2014. The enhance was due primarily to deal-related expenses, in addition to medical affairs and commercial expenses associated with the approval of RAPIVAB and preparation for commercialization of the Company’s HAE product candidates.
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
